Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals, Inc. (SUPN) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company’s news flow reflects its role in neurology and psychiatry, with updates on commercial performance, pipeline progress, and strategic transactions.
Recent press releases highlight quarterly financial results, where Supernus reports net product sales for CNS therapies such as Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products including MYOBLOC, XADAGO, and Osmolex ER. The company also reports collaboration revenue from ZURZUVAE, an oral treatment for postpartum depression, reflecting its collaboration with Biogen Inc. in the U.S. following Supernus’s acquisition of Sage Therapeutics, Inc.
Investors following SUPN news can expect coverage of product launches and commercialization updates, such as the U.S. launch and demand trends for ONAPGO, described as a subcutaneous apomorphine infusion device for motor fluctuations in adults with advanced Parkinson’s disease. Company announcements also discuss supply constraints and prioritization of existing patients when demand exceeds available inventory.
Supernus regularly issues news about its R&D pipeline, including clinical progress for SPN-817 in epilepsy, SPN-820 in depression, and SPN-443 for ADHD/CNS. In addition, the company announces participation in healthcare and therapeutics conferences hosted by investment banks and other organizations, providing forums where management discusses its CNS portfolio, financial performance, and strategy.
This news page aggregates these disclosures so readers can track earnings releases, collaboration developments around ZURZUVAE, clinical trial updates, and investor conference appearances related to Supernus Pharmaceuticals, Inc. (SUPN).
Supernus Pharmaceuticals (Nasdaq: SUPN) has completed its acquisition of Sage Therapeutics, strengthening its position in neuropsychiatric treatments. The deal includes ZURZUVAE®, the first FDA-approved oral medicine for postpartum depression, and a CNS discovery platform.
The transaction structure includes $8.50 per share in cash plus contingent value rights (CVRs) worth up to $3.50 per share tied to specific milestones. The acquisition garnered 58% shareholder approval with 36,313,509 shares tendered. Supernus expects annual cost synergies of up to $200 million and projects the acquisition to be accretive by 2026.
The deal adds collaboration revenue from ZURZUVAE (50% of U.S. net sales through Biogen partnership) and complements Supernus' existing portfolio including Qelbree®, ONAPGO™, and GOCOVRI®.
Supernus Pharmaceuticals (NASDAQ: SUPN) announced the expiration of the Hart-Scott-Rodino waiting period for its proposed acquisition of Sage Therapeutics (NASDAQ: SAGE). The tender offer includes a cash payment of $8.50 per share plus one non-transferable contingent value right (CVR) worth up to $3.50 per share based on milestone achievements.
The CVR milestones include: $0.50 for ZURZUVAE's first commercial sale in Japan by June 2026, $1.00 for U.S. sales exceeding $250M by 2027, $1.00 for U.S. sales over $300M by 2028, and $1.00 for U.S. sales surpassing $375M by 2030. The tender offer expires on July 30, 2025, after which Supernus plans to complete the acquisition through a merger, making Sage its wholly owned subsidiary.
Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET on the same day, featuring CEO Jack Khattar and CFO Tim Dec. The presentation will be available via webcast through the company's investor relations website, with a replay accessible for 60 days following the event.
Supernus Pharmaceuticals (NASDAQ: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, announced its participation in the 2025 Jefferies Global Healthcare Conference. President and CEO Jack A. Khattar will engage in a fireside chat on June 4, 2025, at 2:00 p.m. ET in New York City.
Investors can arrange meetings with management through the Jefferies conference coordinator. The presentation will be available via live audio webcast, accessible through the company's website, with a replay available for 60 days post-conference.
Supernus Pharmaceuticals (SUPN) has received Paragraph IV Notice Letters regarding Abbreviated New Drug Applications (ANDAs) from third parties for its drug Qelbree (viloxazine extended-release capsules) in 100, 150, and 200 mg base formulations. The company plans to vigorously defend its intellectual property rights for Qelbree, which is protected by six U.S. patents listed in the FDA's Orange Book. Three patents expire in September 2029, two in February 2033, and one in April 2035.
Supernus Pharmaceuticals (SUPN) has launched 'Ms. Represented,' a groundbreaking campaign featuring actress Busy Philipps to raise awareness about ADHD in women. The campaign highlights how females often present different ADHD symptoms than males, focusing on inattentive symptoms rather than hyperactivity. Due to this difference, boys are twice as likely to be diagnosed with ADHD than girls, leaving many women undiagnosed or untreated.
The campaign promotes Qelbree®, Supernus's once-daily non-stimulant ADHD treatment for patients 6 years and older. As the first non-stimulant approved for adults with ADHD in 20 years, Qelbree has no evidence of abuse potential and offers convenient prescription refills. The initiative, launched during Mental Health Awareness Month on Bustle, aims to empower women to recognize their ADHD symptoms and seek proper medical attention.
Supernus Pharmaceuticals (SUPN) has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring President and CEO Jack Khattar and Senior VP and CFO Tim Dec.
The presentation will include Q1 2025 financial and business results, followed by a Q&A session. Investors can access the live webcast through the Events & Presentations section of Supernus' Investor Relations website. Pre-registration is available for participants, who will receive a personalized conference code. A replay will be available on the company's website for 60 days following the live call.